Titre : Trouble lié au tabagisme

Trouble lié au tabagisme : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Trouble lié au tabagisme : Questions médicales les plus fréquentes", "headline": "Trouble lié au tabagisme : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Trouble lié au tabagisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-31", "dateModified": "2025-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Trouble lié au tabagisme" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles liés à une substance", "url": "https://questionsmedicales.fr/mesh/D019966", "about": { "@type": "MedicalCondition", "name": "Troubles liés à une substance", "code": { "@type": "MedicalCode", "code": "D019966", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.900" } } }, "about": { "@type": "MedicalCondition", "name": "Trouble lié au tabagisme", "alternateName": "Tobacco Use Disorder", "code": { "@type": "MedicalCode", "code": "D014029", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Joseph Guydish", "url": "https://questionsmedicales.fr/author/Joseph%20Guydish", "affiliation": { "@type": "Organization", "name": "Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: joseph.guydish@ucsf.edu." } }, { "@type": "Person", "name": "Thao Le", "url": "https://questionsmedicales.fr/author/Thao%20Le", "affiliation": { "@type": "Organization", "name": "Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: thao.le@ucsf.edu." } }, { "@type": "Person", "name": "Kevin Delucchi", "url": "https://questionsmedicales.fr/author/Kevin%20Delucchi", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave., San Francisco, CA 94143, United States of America. Electronic address: kevin.delucchi@ucsf.edu." } }, { "@type": "Person", "name": "Guang-Heng Dong", "url": "https://questionsmedicales.fr/author/Guang-Heng%20Dong", "affiliation": { "@type": "Organization", "name": "Department of Psychology, Yunnan Normal University, Kunming, Yunnan Province, PR China. Electronic address: dongguangheng@ynnu.edu.cn." } }, { "@type": "Person", "name": "Caravella McCuistian", "url": "https://questionsmedicales.fr/author/Caravella%20McCuistian", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry and Behavioral Sciences, University of California, San Francisco 1001 Potrero Ave, San Francisco, CA 94110, United States. Electronic address: caravella.mccuistian@ucsf.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway.", "datePublished": "2022-11-10", "url": "https://questionsmedicales.fr/article/36134435", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bju.15899" } }, { "@type": "ScholarlyArticle", "name": "Diagnosis and Pathologic Reporting of Prostate Cancer in the Era of MRI-Targeted Prostate Biopsy.", "datePublished": "2022-10-13", "url": "https://questionsmedicales.fr/article/36344178", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.path.2022.07.002" } }, { "@type": "ScholarlyArticle", "name": "Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series.", "datePublished": "2022-08-01", "url": "https://questionsmedicales.fr/article/35926810", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.humpath.2022.07.018" } }, { "@type": "ScholarlyArticle", "name": "Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.", "datePublished": "2022-06-16", "url": "https://questionsmedicales.fr/article/36326314", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.55730/1300-0144.5374" } }, { "@type": "ScholarlyArticle", "name": "Causal relationship between prostatic diseases and prostate cancer: a mendelian randomization study.", "datePublished": "2024-06-27", "url": "https://questionsmedicales.fr/article/38937672", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-024-12551-9" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Troubles mentaux", "item": "https://questionsmedicales.fr/mesh/D001523" }, { "@type": "ListItem", "position": 3, "name": "Troubles liés à une substance", "item": "https://questionsmedicales.fr/mesh/D019966" }, { "@type": "ListItem", "position": 4, "name": "Trouble lié au tabagisme", "item": "https://questionsmedicales.fr/mesh/D014029" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Trouble lié au tabagisme - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Trouble lié au tabagisme", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Trouble lié au tabagisme", "description": "Comment diagnostiquer un trouble lié au tabagisme ?\nQuels critères sont utilisés pour le diagnostic ?\nQui peut poser le diagnostic ?\nY a-t-il des tests spécifiques pour le diagnostic ?\nLe diagnostic peut-il être fait à distance ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Trouble lié au tabagisme", "description": "Quels sont les symptômes du trouble lié au tabagisme ?\nComment se manifeste le sevrage tabagique ?\nLe tabagisme peut-il affecter l'humeur ?\nY a-t-il des symptômes physiques associés ?\nLes symptômes varient-ils selon les individus ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Trouble lié au tabagisme", "description": "Comment prévenir le trouble lié au tabagisme ?\nLes campagnes anti-tabac sont-elles efficaces ?\nQuel rôle jouent les écoles dans la prévention ?\nLes lois anti-tabac aident-elles à réduire la consommation ?\nLes programmes de cessation sont-ils accessibles ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Trouble lié au tabagisme", "description": "Quels traitements sont disponibles pour le tabagisme ?\nLes médicaments sont-ils efficaces contre le tabagisme ?\nQu'est-ce que la thérapie comportementale ?\nLes groupes de soutien sont-ils utiles ?\nCombien de temps dure un traitement pour le tabagisme ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Trouble lié au tabagisme", "description": "Quelles sont les complications du tabagisme ?\nLe tabagisme affecte-t-il la santé mentale ?\nLe tabagisme peut-il entraîner des problèmes de fertilité ?\nLes complications sont-elles réversibles ?\nLe tabagisme augmente-t-il le risque d'infections ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Trouble lié au tabagisme", "description": "Quels sont les principaux facteurs de risque du tabagisme ?\nL'âge influence-t-il le risque de tabagisme ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes publicités influencent-elles le tabagisme ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un trouble lié au tabagisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation des habitudes de consommation et des symptômes de dépendance." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la consommation régulière, le désir de réduire et les symptômes de sevrage." } }, { "@type": "Question", "name": "Qui peut poser le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel de santé, comme un médecin ou un psychologue, peut poser le diagnostic." } }, { "@type": "Question", "name": "Y a-t-il des tests spécifiques pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de tests spécifiques, le diagnostic est basé sur l'entretien clinique." } }, { "@type": "Question", "name": "Le diagnostic peut-il être fait à distance ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des consultations en ligne peuvent permettre d'évaluer les habitudes de consommation." } }, { "@type": "Question", "name": "Quels sont les symptômes du trouble lié au tabagisme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent le besoin urgent de fumer, l'irritabilité et les symptômes de sevrage." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage tabagique ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, dépression, troubles du sommeil et fringales." } }, { "@type": "Question", "name": "Le tabagisme peut-il affecter l'humeur ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut entraîner des fluctuations d'humeur et des troubles émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des symptômes physiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la toux, l'essoufflement et des douleurs thoraciques peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les individus ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la durée et de l'intensité de la consommation." } }, { "@type": "Question", "name": "Comment prévenir le trouble lié au tabagisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par l'éducation, la sensibilisation et des politiques anti-tabac efficaces." } }, { "@type": "Question", "name": "Les campagnes anti-tabac sont-elles efficaces ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sensibilisent le public aux dangers du tabagisme et encouragent l'arrêt." } }, { "@type": "Question", "name": "Quel rôle jouent les écoles dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les écoles peuvent éduquer les jeunes sur les dangers du tabac et promouvoir des modes de vie sains." } }, { "@type": "Question", "name": "Les lois anti-tabac aident-elles à réduire la consommation ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des lois strictes sur la vente et la consommation de tabac réduisent son usage." } }, { "@type": "Question", "name": "Les programmes de cessation sont-ils accessibles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux programmes de cessation sont disponibles dans les centres de santé et en ligne." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le tabagisme ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale." } }, { "@type": "Question", "name": "Les médicaments sont-ils efficaces contre le tabagisme ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments comme la varénicline et le bupropion sont efficaces pour réduire le besoin de fumer." } }, { "@type": "Question", "name": "Qu'est-ce que la thérapie comportementale ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "C'est une approche qui aide à modifier les comportements liés à la consommation de tabac." } }, { "@type": "Question", "name": "Les groupes de soutien sont-ils utiles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les groupes de soutien offrent un environnement d'encouragement et de partage d'expériences." } }, { "@type": "Question", "name": "Combien de temps dure un traitement pour le tabagisme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement varie, mais il est souvent recommandé de suivre un programme de plusieurs mois." } }, { "@type": "Question", "name": "Quelles sont les complications du tabagisme ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies cardiovasculaires, des cancers et des maladies respiratoires." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il la santé mentale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est associé à des troubles de l'humeur, de l'anxiété et des problèmes de dépendance." } }, { "@type": "Question", "name": "Le tabagisme peut-il entraîner des problèmes de fertilité ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut réduire la fertilité chez les hommes et les femmes, affectant la reproduction." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec l'arrêt du tabac, mais pas toutes." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque d'infections ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il affaiblit le système immunitaire, augmentant le risque d'infections respiratoires." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du tabagisme ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'exposition à la fumée, l'hérédité et des influences sociales." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de tabagisme ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes adultes sont plus susceptibles de commencer à fumer en raison de la pression sociale." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut inciter à fumer comme moyen de gestion des émotions et de l'anxiété." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avoir des membres de la famille fumeurs augmente le risque de développer une dépendance." } }, { "@type": "Question", "name": "Les publicités influencent-elles le tabagisme ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les publicités peuvent normaliser le tabagisme et inciter les jeunes à commencer à fumer." } } ] } ] }

Sources (10000 au total)

The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway.

To report outcomes within the Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) diagnostic pathway, introduced to reduce patient and healthcare burdens and standardize delivery of pre-biopsy... A total of 2130 patients from three centres who completed the RAPID pathway (3 April 2017 to 31 March 2020) were consecutively entered as a prospective registry. These patients were also compared to a... The median patient age and PSA level were 66 years and 6.6 ng/mL, respectively. Biopsy could be omitted in 43% of patients (920/2130). A further 7.9% of patients (168/2130) declined a recommendation f... The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers, although ...

Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.

It is a known fact that the role of microRNAs (miRNA) has a very important place in cancer development and progression. miRNAs target a significant part of pathways as well as genes. This study aimed ... Peripheral blood mononuclear cells (PBMCs) and tissue samples were collected from prostate cancer (PCa) (n: 20) and benign prostatic hyperplasia (BPH) (n: 20) patients. Total RNA isolation was perform... In tissue samples, 37 different expressed miRNAs were identified in PCa patients compared to BPH patients. In PBMCs samples, 27 different expressed miRNAs were identified in PCa patients compared to b... Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A, AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategie...

Causal relationship between prostatic diseases and prostate cancer: a mendelian randomization study.

Although it is thought that prostatitis or benign prostatic hyperplasia (BPH) is related to prostate cancer (PCa), the underlying causal effects of these diseases are unclear.... We assessed the causal relationship between prostatitis or BPH and PCa using a two-sample Mendelian randomization (MR) approach. The data utilized in this study were sourced from genome-wide associati... MR analysis showed that BPH had a significant causal effect on PCa (Odds Ratio = 1.209, 95% Confidence Interval: 0.098-0.281, P = 5.079 × 10... This MR study supports that BPH has a positive causal effect on PCa, while genetically predicted prostatitis has no causal effect on PCa. Nonetheless, further studies should explore the underlying bio...

Prostate MRI for the detection of clinically significant prostate cancer: Update and future directions.

In recent decades, there has been an increasing role for magnetic resonance imaging (MRI) in the detection of clinically significant prostate cancer (csPC). The purpose of this review is to provide an... In diagnosing clinically significant prostate cancer pre-biopsy, advances include our understanding of MRI-targeted biopsy, the role of biparametric MRI (non-contrast) and changing indications, for ex... The utility of MRI in detecting csPC has been demonstrated in many clinical scenarios, initially from simply diagnosing csPC pre-biopsy, now to screening, active surveillance, clinical staging, and de...

Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer.

For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, ... Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performe... The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognos... PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The re...

Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.

To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa).... The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group an... tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity ... With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical di...

[Structured reporting of prostate cancer-self-development of a digital solution for prostate biopsies].

The challenges in pathology and in structuring of data are increasing. Although considerable amounts of data are generated during the pathological diagnostic process, these data are often not availabl... The aim of the work was the development of a digital system for the direct and high-quality acquisition of structured pathology data using the example of biopsy-based diagnostics of prostate carcinoma... A solution was created in cooperation with the pathology laboratory information system (LIS) provider imassense GmbH (Berlin, Germany), whose LIS 'Informationssystem der digitalen Pathologie' (IS-P) i... Over a period of about 1.5 years, a system that is capable of structured reporting according to local, national (S3 guidelines, German Cancer Society) and international (International Collaboration on...